Teva Pharmaceuticals (TASE: TEVA) has partnered with Klinge Biopharma and Formycon (FSE: FYB) to commercialize FYB203, a biosimilar to Eylea (aflibercept), in Europe and Israel.
The drug will be marketed as Ahzantive, pending regulatory approval, and targets retinal diseases such as neovascular age-related macular degeneration.
The collaboration, which combines Teva’s extensive European distribution network with Formycon’s biosimilar development expertise, builds on the firms' earlier success with Ranivisio (ranibizumab) commercialization in Europe.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze